Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Hepatic Cystadenomas Workup

  • Author: Krishan Ariyarathna, MD; Chief Editor: BS Anand, MD  more...
 
Updated: Jun 16, 2016
 

Laboratory Studies

Although liver test results may be normal in patients with biliary cystadenomas, elevation of alkaline phosphatase, bilirubin, and, less commonly, aminotransferase levels can be present.

Superinfection of the tumor may cause leukocytosis with a left shift. Anemia is extremely rare but theoretically possible secondary to bleeding.

Carbohydrate antigen (CA) 19-9 levels may be elevated in some cases. Carcinoembryonic antigen (CEA) and alpha-fetoprotein levels are usually normal.

Cyst fluid analysis at laparoscopy has been proposed in the surgical management of hepatic cysts. Elevated intracystic CA19-9 values were found in biliary cystadenomas compared to those of simple cysts.

Fuks et al found that intracystic fluid concentrations of tumor-associated glycoprotein (TAG) 72 can be used to differentiate hepatic simple cysts from mucinous cysts. Intracystic fluid samples were taken from 118 patients undergoing partial or complete resection of cystic liver lesions, including hepatic simple cysts (75 patients), mucinous cysts (27 patients, including 19 with biliary cystadenomas, four with biliary cystadenocarcinomas, and four with intraductal papillary mucinous neoplasms of the bile duct), and miscellaneous cysts (16 patients). The investigators found that hepatic simple cysts could be differentiated from mucinous cysts—with a sensitivity and specificity of 0.79 and 0.97, respectively—based on a TAG-72 concentration of more than 25 U/mL.[5]

Next

Imaging Studies

Imaging studies are the key element of the workup. On US, hepatic cystadenomas appear as anechoic lesions with internal septations. Focal hyperechoic areas within the lesion are common and can represent focal wall fibrosis, intracystic hemorrhage, or papillary projections.

Computed tomography (CT) scanning

On CT scanning, the tumor appears as low-attenuation water density areas with focal enhancement after contrast administration. The septa and the mural nodules often are visualized. Involvement or compression of the portal vein and biliary tree can be appreciated best by CT scan.

Magnetic resonance imaging (MRI)

MRI can help provide additional information about the nature of the cystic fluid (ie, hemorrhagic vs serous or mucinous). Lesions appear hyperintense on T2-weighted images and hypointense on T1-weighted images, sometimes with reduced perilesional rim signal intensity on T2-weighted images. Intracystic hemorrhage produces higher signal intensity on T1-weighted images than mucinous or bilious fluid content.

Ultrasonography (US)

US is more sensitive in identifying internal septations, whereas CT scan provides anatomical relation to the liver.

A study by Xu et al comparing the imaging features of six intrahepatic biliary cystadenomas with those of seven intrahepatic biliary cystadenocarcinomas indicated that, as seen on conventional US, cystadenomas tend more often to be multilocular than do cystadenocarcinomas, while cystadenocarcinomas are more likely to have a mural or septal nodule and a nodule diameter of over 1 cm.[6]

Previous
Next

Other Tests

Endoscopic retrograde cholangiopancreatography (ERCP)

Endoscopic retrograde cholangiopancreatography (ERCP) may demonstrate intraluminal filling defects or a cystic cavity communicating with the biliary tree. Apart from helping in the diagnosis of a cystadenocarcinoma, ERCP is also helpful in decompressing the biliary system in patients with biliary obstruction.

Magnetic resonance cholangiopancreatography (MRCP)

Magnetic resonance cholangiopancreatography (MRCP) is an alternative to ERCP in the evaluation of pancreatic and biliary duct systems. Even though the resolution of MRCP is somewhat inferior to ERCP, the procedure is noninvasive and less expensive.

Previous
Next

Procedures

Fine-needle aspiration biopsy

Initial imaging studies should be followed by fine-needle aspiration (FNA) biopsy of the liver, which may help provide important information about the nature of the lesion.

Cytology of the fluid or FNA of prominent papillary projections or wall nodules is useful in helping clarify the diagnosis, even though dissemination of malignant cells through the needle track is a theoretical concern.

The authors usually choose to proceed with FNA biopsy whenever a question exists regarding the diagnosis of a hepatic tumor. However, remember that needle biopsy findings from hepatic cystadenomas may be misleading because foci of adenocarcinomas can be easily missed.

If the diagnostic suspicion of a hepatic cystadenoma is high, a direct referral for surgical resection is indicated.

Other

A laparoscopic approach with cyst fluid analysis for CA19-9 and CEA followed by cyst wall tissue sampling has been proposed. Elevated CA19-9 levels and premalignant or malignant histology should be followed by radical resection.

Previous
Next

Histologic Findings

Solid hepatic lesions may be considered in the differential diagnosis, especially when the lesions appear irregular on imaging studies. Such lesions include FNH, adenomas, angiomyolipomas, and primary hepatic malignancies, such as hepatocellular carcinoma and cholangiocarcinoma.

A histological variant of biliary cystadenoma occurring primarily in women has been described as cystadenoma with mesenchymal stroma. This variant is characterized by the presence of spindle cells in the mesenchymal stroma that are capable of differentiating into different cell types, with a high premalignant potential.

Differentiation of cystadenomas from cystadenocarcinomas is particularly difficult. Imaging studies are not sensitive enough to completely exclude the presence of malignant degeneration in a cystadenoma. Determination of the tumor marker CA19-9 in the serum and in the cyst fluid has been suggested, but CA19-9 also can be expressed in the biliary epithelium lining of benign cystadenomas. For this reason, the presence of CA19-9 is not 100% reliable in the diagnosis of cystadenocarcinoma.

Embryonal sarcoma also is in the differential diagnosis.

Cystadenomas may express a progesterone receptor in the mesenchymal cell component. Other markers demonstrated on immunohistochemistry are CA19-9, CEA, vimentin, and cytokeratin. In situ hybridization has demonstrated selective positivity for albumin messenger RNA in cystadenocarcinomas.

Available evidence shows that biliary cystadenomas tend to occur predominantly in women because these tumors are hormonally responsive. This theory is further supported by immunohistochemical studies demonstrating positive estrogen/progesterone receptors associated with biliary cystadenomas.

Previous
 
 
Contributor Information and Disclosures
Author

Krishan Ariyarathna, MD Staff Physician, Department of Internal Medicine, Creighton University Medical Center

Krishan Ariyarathna, MD is a member of the following medical societies: American College of Physicians, American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Additional Contributors

John Gunn Lee, MD Director of Pancreaticobiliary Service, Associate Professor, Department of Internal Medicine, Division of Gastroenterology, University of California at Irvine School of Medicine

John Gunn Lee, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Acknowledgements

Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

Sandeep Mukherjee, MB, BCh, MPH, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

The authors and editors of Medscape Reference gratefully acknowledge the contributions of the previous author and coauthors, Andrea Duchini, MD, John Goss, MD, Murat Kilic, MD, Philip Seu, MD, and Paul J Pockros, MD, to the development and writing of this article.

References
  1. Ratti F, Ferla F, Paganelli M, Cipriani F, Aldrighetti L, Ferla G. Biliary cystadenoma: short- and long-term outcome after radical hepatic resection. Updates Surg. 2012 Mar. 64(1):13-8. [Medline].

  2. Fukunaga N, Ishikawa M, Ishikura H, et al. Hepatobiliary cystadenoma exhibiting morphologic changes from simple hepatic cyst shown by 11-year follow up imagings. World J Surg Oncol. 2008 Dec 11. 6:129. [Medline]. [Full Text].

  3. Choi HK, Lee JK, Lee KH, et al. Differential diagnosis for intrahepatic biliary cystadenoma and hepatic simple cyst: significance of cystic fluid analysis and radiologic findings. J Clin Gastroenterol. 2010 Apr. 44(4):289-93. [Medline].

  4. Zhang YL, Yuan L, Shen F, Wang Y. Hemorrhagic hepatic cysts mimicking biliary cystadenoma. World J Gastroenterol. 2009 Sep 28. 15(36):4601-3. [Medline]. [Full Text].

  5. Fuks D, Voitot H, Paradis V, et al. Intracystic concentrations of tumour markers for the diagnosis of cystic liver lesions. Br J Surg. 2014 Mar. 101(4):408-16. [Medline].

  6. Xu HX, Lu MD, Liu LN, et al. Imaging features of intrahepatic biliary cystadenoma and cystadenocarcinoma on B-mode and contrast-enhanced ultrasound. Ultraschall Med. 2012 Dec. 33(7):E241-9. [Medline].

  7. Gamblin TC, Holloway SE, Heckman JT, Geller DA. Laparoscopic resection of benign hepatic cysts: a new standard. J Am Coll Surg. 2008 Nov. 207(5):731-6. [Medline].

  8. Abu Hilal M, Di Fabio F, Teng MJ, Godfrey DA, Primrose JN, Pearce NW. Surgical management of benign and indeterminate hepatic lesions in the era of laparoscopic liver surgery. Dig Surg. 2011. 28(3):232-6. [Medline].

  9. Abdul-Al HM, Makhlouf HR, Goodman ZD. Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study. Virchows Arch. 2007 Jun. 450(6):691-7. [Medline].

  10. Baudin G, Novellas S, Buratti MS, et al. Atypical MRI features of a biliary cystadenoma revealed by jaundice. Clin Imaging. 2006 Nov-Dec. 30(6):413-5. [Medline].

  11. Catinis GE, Frey DJ, Skinner JW, Balart LA. Hepatic cystadenoma: an unusual presentation. Am J Gastroenterol. 1998 May. 93(5):827-9. [Medline].

  12. D'Errico A, Deleonardi G, Fiorentino M, Scoazec JY, Grigioni WF. Diagnostic implications of albumin messenger RNA detection and cytokeratin pattern in benign hepatic lesions and biliary cystadenocarcinoma. Diagn Mol Pathol. 1998 Dec. 7(6):289-94. [Medline].

  13. Dardik H, Glotzer P, Silver C. Congenital hepatic cyst causing jaundice: report of a case and analogies with respiratory malformation. Ann Surg. 1964 Apr. 159:585-92. [Medline].

  14. Franko J, Nussbaum ML, Morris JB. Choledochal cyst cholangiocarcinoma arising from adenoma: case report and a review of the literature. Curr Surg. 2006 Jul-Aug. 63(4):281-4. [Medline].

  15. Grayson W, Teare J, Myburgh JA, Paterson AC. Immunohistochemical demonstration of progesterone receptor in hepatobiliary cystadenoma with mesenchymal stroma. Histopathology. 1996 Nov. 29(5):461-3. [Medline].

  16. Horsmans Y, Laka A, Gigot JF, Geubel AP. Serum and cystic fluid CA 19-9 determinations as a diagnostic help in liver cysts of uncertain nature. Liver. 1996 Aug. 16(4):255-7. [Medline].

  17. Ishak KG, Willis GW, Cummins SD, Bullock AA. Biliary cystadenoma and cystadenocarcinoma: report of 14 cases and review of the literature. Cancer. 1977 Jan. 39(1):322-38. [Medline].

  18. Jenkins RL, Johnson LB, Lewis WD. Surgical approach to benign liver tumors. Semin Liver Dis. 1994 May. 14(2):178-89. [Medline].

  19. Kanamori H, Kawahara H, Oh S, et al. A case of biliary cystadenocarcinoma with recurrent jaundice. Diagnostic evaluation of computed tomography. Cancer. 1985 Jun 1. 55(11):2722-4. [Medline].

  20. Karahan OI, Kahriman G, Soyuer I, Ok E. Hepatic von Meyenburg complex simulating biliary cystadenocarcinoma. Clin Imaging. 2007 Jan-Feb. 31(1):50-3. [Medline].

  21. Koffron A, Rao S, Ferrario M, Abecassis M. Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era. Surgery. 2004 Oct. 136(4):926-36. [Medline].

  22. Mills GC, Alperin JB, Trimmer KB. Studies on variant glucose-6-phosphate dehydrogenases: G6PD Fort Worth. Biochem Med. 1975 Jul. 13(3):264-75. [Medline].

  23. Ramacciato G, Nigri GR, D'Angelo F, et al. Emergency laparotomy for misdiagnosed biliary cystadenoma originating from caudate lobe. World J Surg Oncol. 2006 Nov 7. 4:76. [Medline].

  24. Sanchez H, Gagner M, Rossi RL, et al. Surgical management of nonparasitic cystic liver disease. Am J Surg. 1991 Jan. 161(1):113-8; discussion 118-9. [Medline].

  25. Shimada M, Takenaka K, Gion T, et al. Treatment strategy for patients with cystic lesions mimicking a liver tumor: a recent 10-year surgical experience in Japan. Arch Surg. 1998 Jun. 133(6):643-6. [Medline].

  26. Teoh AY, Ng SS, Lee KF, Lai PB. Biliary cystadenoma and other complicated cystic lesions of the liver: diagnostic and therapeutic challenges. World J Surg. 2006 Aug. 30(8):1560-6. [Medline].

  27. Terada T, Kitamura Y, Ohta T. Endocrine cells in hepatobiliary cystadenomas and cystadenocarcinomas. Virchows Arch. 1997 Jan. 430(1):37-40. [Medline].

  28. Wheeler DA, Edmondson HA. Cystadenoma with mesenchymal stroma (CMS) in the liver and bile ducts. A clinicopathologic study of 17 cases, 4 with malignant change. Cancer. 1985 Sep 15. 56(6):1434-45. [Medline].

  29. Woods GL. Biliary cystadenocarcinoma: Case report of hepatic malignancy originating in benign cystadenoma. Cancer. 1981 Jun 15. 47(12):2936-40. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.